ESPERION THERAPEUTICS INC (ESPR)
US29664W1053 - Common Stock
ESPR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ESPR have multiple concerns. ESPR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ESPR has reported negative net income.
In the past year ESPR has reported a negative cash flow from operations.
ESPR had negative earnings in each of the past 5 years.
ESPR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ESPR has a Return On Assets (-27.62%) which is comparable to the rest of the industry.
ESPR has a better Return On Invested Capital (8.77%) than 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.62% | ||
| ROE | N/A | ||
| ROIC | 8.77% |
ROA(3y)-88.82%
ROA(5y)-70.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 5.57%, ESPR is in the better half of the industry, outperforming 79.69% of the companies in the same industry.
ESPR's Gross Margin of 81.58% is amongst the best of the industry. ESPR outperforms 87.50% of its industry peers.
ESPR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.57% | ||
| PM (TTM) | N/A | ||
| GM | 81.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.07%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ESPR is still creating some value.
ESPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ESPR has been increased compared to 5 years ago.
Compared to 1 year ago, ESPR has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.97, we must say that ESPR is in the distress zone and has some risk of bankruptcy.
ESPR's Altman-Z score of -4.97 is on the low side compared to the rest of the industry. ESPR is outperformed by 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.97 |
ROIC/WACC1.06
WACC8.27%
2.3 Liquidity
ESPR has a Current Ratio of 1.85. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
ESPR has a worse Current ratio (1.85) than 65.10% of its industry peers.
ESPR has a Quick Ratio of 1.37. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.37, ESPR is doing worse than 71.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
ESPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.11%, which is quite impressive.
The Revenue has grown by 187.12% in the past year. This is a very strong growth!
Measured over the past years, ESPR shows a very negative growth in Revenue. The Revenue has been decreasing by -20.03% on average per year.
EPS 1Y (TTM)73.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
Revenue 1Y (TTM)187.12%
Revenue growth 3Y-20.03%
Revenue growth 5YN/A
Sales Q2Q%52%
3.2 Future
Based on estimates for the next years, ESPR will show a very strong growth in Earnings Per Share. The EPS will grow by 29.76% on average per year.
Based on estimates for the next years, ESPR will show a very strong growth in Revenue. The Revenue will grow by 64.10% on average per year.
EPS Next Y86.98%
EPS Next 2Y43.87%
EPS Next 3Y31.88%
EPS Next 5Y29.76%
Revenue Next Year201.57%
Revenue Next 2Y94.8%
Revenue Next 3Y65.61%
Revenue Next 5Y64.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ESPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 16.29, which indicates a correct valuation of ESPR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ESPR indicates a rather cheap valuation: ESPR is cheaper than 82.29% of the companies listed in the same industry.
ESPR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ESPR is valued a bit cheaper than 77.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.95 |
4.3 Compensation for Growth
ESPR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ESPR's earnings are expected to grow with 31.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.87%
EPS Next 3Y31.88%
5. Dividend
5.1 Amount
No dividends for ESPR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ESPERION THERAPEUTICS INC
NASDAQ:ESPR (11/20/2024, 8:19:17 PM)
Premarket: 2.4 -0.01 (-0.41%)2.41
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap474.87M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.29 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.62% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 5.57% | ||
| PM (TTM) | N/A | ||
| GM | 81.58% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)73.11%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y86.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)187.12%
Revenue growth 3Y-20.03%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y